These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 15256455)

  • 21. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A; Sørensen JB
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of genes that modulate sensitivity of U373MG glioblastoma cells to cis-platinum.
    Ma Y; Yuan RQ; Fan S; Hu C; Goldberg ID; Laterra JJ; Rosen EM
    Anticancer Drugs; 2006 Aug; 17(7):733-51. PubMed ID: 16926624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Enhanced cisplatin cytotoxicity by RNA interfering the excision repair cross-complementing 1 gene in ovarian cancer cell lines].
    Liu GY; Qu QX; Mi RR; Qi J
    Zhonghua Fu Chan Ke Za Zhi; 2006 May; 41(5):339-42. PubMed ID: 16762192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [RNA interference silencing excision repair cross-complementing 1 gene and affecting cisplatin sensitivity on lung cancer cell lines].
    Shang XB; Yu ZT; Tang P; Zhang XZ
    Zhonghua Yi Xue Za Zhi; 2008 Oct; 88(39):2799-802. PubMed ID: 19080461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergistic activation of the murine gastrin promoter by oncogenic Ras and beta-catenin involves SMAD recruitment.
    Chakladar A; Dubeykovskiy A; Wojtukiewicz LJ; Pratap J; Lei S; Wang TC
    Biochem Biophys Res Commun; 2005 Oct; 336(1):190-6. PubMed ID: 16139800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of apoptosis and suppression of ERCC1 expression by the potent amonafide analogue 8-c in human colorectal carcinoma cells.
    Wang Z; Liang X; Cheng Z; Xu Y; Yin P; Zhu H; Li Q; Qian X; Liu J
    Anticancer Drugs; 2013 Apr; 24(4):355-65. PubMed ID: 23426174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metformin-mediated downregulation of p38 mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel.
    Tseng SC; Huang YC; Chen HJ; Chiu HC; Huang YJ; Wo TY; Weng SH; Lin YW
    Biochem Pharmacol; 2013 Feb; 85(4):583-94. PubMed ID: 23228696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response.
    Felip E; Rosell R
    Expert Rev Mol Diagn; 2007 May; 7(3):261-8. PubMed ID: 17489733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
    Handra-Luca A; Hernandez J; Mountzios G; Taranchon E; Lacau-St-Guily J; Soria JC; Fouret P
    Clin Cancer Res; 2007 Jul; 13(13):3855-9. PubMed ID: 17606717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cisplatin transiently up-regulates hHR23 expression through enhanced translational efficiency in A549 adenocarcinoma cells.
    Shen YH; Chen BR; Cherng SH; Chueh PJ; Tan X; Lin YW; Lin JC; Chuang SM
    Toxicol Lett; 2011 Sep; 205(3):341-50. PubMed ID: 21742020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER-2/neu transcriptionally activates Jab1 expression via the AKT/beta-catenin pathway in breast cancer cells.
    Hsu MC; Chang HC; Hung WC
    Endocr Relat Cancer; 2007 Sep; 14(3):655-67. PubMed ID: 17914096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.
    Simon G; Sharma A; Li X; Hazelton T; Walsh F; Williams C; Chiappori A; Haura E; Tanvetyanon T; Antonia S; Cantor A; Bepler G
    J Clin Oncol; 2007 Jul; 25(19):2741-6. PubMed ID: 17602079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TATA box-binding protein-associated factor 12 is important for RAS-induced transformation properties of colorectal cancer cells.
    Voulgari A; Voskou S; Tora L; Davidson I; Sasazuki T; Shirasawa S; Pintzas A
    Mol Cancer Res; 2008 Jun; 6(6):1071-83. PubMed ID: 18567809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
    Darcy KM; Tian C; Reed E
    Cancer Res; 2007 May; 67(9):4474-81. PubMed ID: 17483363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of the two nucleotide excision repair genes ERCC1 and XPC in human hepatocellular carcinoma.
    Fautrel A; Andrieux L; Musso O; Boudjema K; Guillouzo A; Langouët S
    J Hepatol; 2005 Aug; 43(2):288-93. PubMed ID: 15922480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.
    Lee KH; Min HS; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Heo DS; Bang YJ; Sung SW; Kim JH
    Lung Cancer; 2008 Jun; 60(3):401-7. PubMed ID: 18036700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
    Cobo M; Isla D; Massuti B; Montes A; Sanchez JM; Provencio M; Viñolas N; Paz-Ares L; Lopez-Vivanco G; Muñoz MA; Felip E; Alberola V; Camps C; Domine M; Sanchez JJ; Sanchez-Ronco M; Danenberg K; Taron M; Gandara D; Rosell R
    J Clin Oncol; 2007 Jul; 25(19):2747-54. PubMed ID: 17602080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.
    Reardon JT; Vaisman A; Chaney SG; Sancar A
    Cancer Res; 1999 Aug; 59(16):3968-71. PubMed ID: 10463593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.